Singapore emerges as key hub in Asia-Pacific’s next medtech wave

The city-state’s regulatory strength helps translate medical innovations into globally validated products.

Singapore is emerging as a key medtech hub in Asia-Pacific as the region shifts from absorbing global medical innovations to creating and exporting its own, according to a report by Bain & Company.

The report said Singapore has built a strong medtech ecosystem by combining advanced regulatory standing, clinical translation infrastructure, precision engineering, and end-to-end productisation platforms.

This allows the city-state to help turn promising prototypes into globally validated medical devices.

Asia-Pacific’s medtech demand is expected to reach US$132b by 2030, growing at a 6.9% CAGR, faster than the global rate of 5.5%.

The region currently accounts for about 16%, or US$94b, of the US$583b global medical device market, excluding in vitro diagnostics and laboratory equipment.

Bain said Singapore’s advantage lies in its integrated innovation and productisation hub, which gives companies access to multinational R&D infrastructure, multi-site trial networks, precision engineering manufacturing partners, and an advanced regulatory framework.

The ecosystem is supported by platforms such as Singapore Biodesign and Duke-NUS, which train clinicians to identify unmet healthcare needs and turn ideas into investable products.

Through A*STAR’s Singapore Biodesign platform, more than 2,600 individuals have been trained since 2010, leading to over 76 funded projects and 20 spin-offs. Singapore’s talent pipeline is also backed by $1b in government commitments under its National AI Strategy 2.0 from 2025 to 2030.

A*STAR’s MedTech Catapult provides seed capital, engineering resources, and product development support, whilst its Diagnostics Development Hub supports digital health and point-of-care diagnostics.

SG Growth Capital, through its partnership with Santé Ventures and planned Santé Accel programme, also provides venture, clinical, regulatory, engineering, and commercial support to early-stage medtech founders.

Singapore’s regulatory framework is another key strength. Bain noted that the Health Sciences Authority has achieved WHO Maturity Level 4 for medical device regulatory systems, with regulators in markets such as Malaysia, Australia, Hong Kong, the Philippines, Thailand, and Sri Lanka referencing HSA approvals. This can help shorten market-entry timelines for companies.

The report also highlighted Singapore’s AI-SaMD Exemption Sandbox, which allows public healthcare institutions to deploy low- to moderately low-risk AI-driven medical devices for in-house use with some exemptions from typical registration requirements. Singapore’s intellectual property regime also ranks among the top five globally for innovation and IP rights.

Singapore’s manufacturing base further strengthens its role in the global medtech supply chain. Around one in seven hearing aids and one in five cardiac-related implants used globally are produced in the country.

Leading medtech firms such as Biotronik and Resmed, as well as electronics manufacturing services companies such as Jabil and Flex, have manufacturing and R&D operations in Singapore.

Bain said Singapore’s appeal now extends beyond regional headquarters, distribution, or business development.

Its strengths cover precision engineering, regulated manufacturing, supplier reliability, quality systems, and global logistics—capabilities that are critical for scaling advanced medtech products.

However, the report said Asia-Pacific medtech firms still face structural gaps, including underfunding, shortages in clinical and regulatory talent, late-stage IP strategies, infrastructure deficits, and reimbursement delays.

For Singapore and the wider region to produce global medtech champions, Bain said stakeholders must invest early in clinical evidence, regulatory capability, reimbursement planning, and global commercialisation support.